ING Groep NV Purchases Shares of 12,500 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

ING Groep NV bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,500 shares of the biopharmaceutical company's stock, valued at approximately $1,044,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Handelsbanken Fonder AB boosted its position in shares of Intra-Cellular Therapies by 3.0% during the fourth quarter. Handelsbanken Fonder AB now owns 27,100 shares of the biopharmaceutical company's stock worth $2,263,000 after buying an additional 800 shares during the period. Ieq Capital LLC raised its holdings in Intra-Cellular Therapies by 469.4% during the fourth quarter. Ieq Capital LLC now owns 32,398 shares of the biopharmaceutical company's stock worth $2,706,000 after purchasing an additional 26,708 shares in the last quarter. TimesSquare Capital Management LLC lifted its position in Intra-Cellular Therapies by 91.8% in the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company's stock valued at $70,179,000 after acquiring an additional 402,186 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Intra-Cellular Therapies by 7.2% during the fourth quarter. New York State Common Retirement Fund now owns 76,563 shares of the biopharmaceutical company's stock worth $6,395,000 after purchasing an additional 5,162 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $96,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ITCI. Baird R W downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Piper Sandler reissued a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Leerink Partnrs downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Royal Bank of Canada restated a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Monday. They issued a "hold" rating on the stock. Ten analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Stock Down 0.2 %

Shares of ITCI stock traded down $0.21 during mid-day trading on Thursday, hitting $128.25. 1,278,873 shares of the company's stock were exchanged, compared to its average volume of 3,911,228. The stock has a market cap of $13.64 billion, a price-to-earnings ratio of -147.41 and a beta of 0.72. The stock has a 50-day simple moving average of $112.80 and a two-hundred day simple moving average of $90.87. Intra-Cellular Therapies, Inc. has a fifty-two week low of $63.30 and a fifty-two week high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. As a group, analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.